Director's Dealing

Ergomed

19/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230419:nRSS6627Wa&default-theme=true

RNS Number : 6627W  Ergomed plc  19 April 2023

Director's Dealing

 

 

Guildford, UK - 19 April 2023: Ergomed plc (LSE: ERGO) ("Ergomed" or the
"Company"), a company focused on providing specialised services to the
pharmaceutical industry, announces that on 19 April 2023, Dr Miroslav
Reljanović, Executive Chairman of Ergomed, transferred 400,000 ordinary
shares of 1p each in the Company ("Ordinary Shares") to a former director of
the Company.  The transfer took place following an exercise of options under
an option agreement dated 5 August 2019 between Dr Reljanović and the former
director and the exercise price was 1p per ordinary share.

 

Following the transfer, Dr Reljanović holds 9,129,297 ordinary shares
representing 17.98% of the Company's issued share capital.

 

The relevant notifications set out below are provided in accordance with the
requirements of Article 19 of the UK Market Abuse Regulation.

 

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Dr Miroslav Reljanović
 2   Reason for the notification
 a)  Position/status                                              Executive Chairman
 b)  Initial notification /Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Ergomed plc
 b)  Legal Entity Identifier                                      213800BVS8I9VMC1AP84
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of 1 pence each

     Identification code

                                                                   GB00BN7ZCY67
 b)  Nature of the transaction                                    Transfer of shares
 c)  Currency                                                     GBP
 d)  Price(s) and volume(s)                                       Price(s)                    Volume(s)
     £0.01                                                                                    400,000

 e)  Aggregated information

     - Aggregated volume                                          400,000

     - Price                                                      £0.01

     - Aggregated total                                           £4,000

 f)  Date of the transaction                                      19 April 2023
 g)  Place of the transaction                                     London Stock Exchange, AIM

 

 

 

 

ENDS

 

Enquiries:

 Ergomed plc                                                                 Tel: +44 (0) 1483 402 975
 Miroslav Reljanović (Executive Chairman)
 Jonathan Curtain (Chief Financial Officer)

 Keith Byrne (Senior Vice President, Capital Markets and Strategy)

 Numis Securities Limited (Nominated Adviser and Joint Broker)              Tel: +44 (0) 20 7260 1000
 Freddie Barnfield / Euan Brown / Jack McLaren

 Peel Hunt Securities Limited (Joint Broker)

 James Steel / Dr Christopher                                               Tel: +44 (0) 20 7418 8900
 Golden

 Consilium Strategic Communications - for UK enquiries                      Tel: +44 (0) 20 3709 5700
 Chris Gardner / Matthew Neal                                               ergomed@consilium-comms.com

 

About Ergomed plc

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning
all phases of clinical development, post-approval pharmacovigilance and
medical information. Ergomed's fast-growing services business includes an
industry-leading suite of specialist pharmacovigilance (PV) solutions,
integrated under the PrimeVigilance brand, a full range of high-quality
clinical research and trial management services under the Ergomed brand (CRO)
and mission-critical regulatory compliance and consulting services under the
ADAMAS brand. For further information, visit: http://ergomedplc.com
(http://ergomedplc.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAPLPFFFDEFA